Previous Article | Next Article ![]()
Clinical and Vaccine Immunology, January 2009, p. 78-87, Vol. 16, No. 1
1071-412X/09/$08.00+0 doi:10.1128/CVI.00253-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

School of Applied Sciences, RMIT University, Bundoora, Victoria, Australia
Received 12 July 2008/ Returned for modification 8 October 2008/ Accepted 30 October 2008
Attenuated Salmonella strains are currently in production as vaccines for protection of animals against salmonellosis. Such commercial strains offer the potential to deliver heterologous antigen to protect animals against other diseases. One vaccine strain, attenuated Salmonella enterica serovar Typhimurium (STM-1), was tested for the ability to deliver ovalbumin and to induce immune responses in mice. Two vaccine trials were performed testing the influence of promoter choice, the location of the encoding DNA (plasmid or chromosome), and the effect of preexisting homologous or heterologous immunity. The results demonstrated that humoral and T-cell responses were induced from either of two promoters, from either the plasmid or the chromosome, and that preexposure to the empty homologous vector, STM-1, or the heterologous vector, S. enterica serovar Enteritidis, had no detrimental effect on subsequent antigen-specific responses. In the case of homologous preexposure, responses were generally greater, and this was correlated with an increased uptake of Salmonella by macrophages in vitro after opsonization with immune sera.
Published ahead of print on 12 November 2008.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»